Riskpilot← Back to searchSign inGet full accessTRIO PHARMA ApS
APSActiveCVR 36499281Vermlandsgade 51Wholesale of other food · NACE 4638Est. 20152 employees
Revenue 2025
DKK -412K
+43% vs 2024
EBITDA margin
249.9%
-24% vs 2024
Equity ratio
-174.1%
Financial strength
Net profit 2025
DKK -1,2M
-139% vs 2024
| Revenue | DKK -412K | +43% |
| EBITDA | DKK -1M | -24% |
| Net profit | DKK -1,2M | -139% |
| Total assets | DKK 1,5M | +15% |
| Equity | DKK -2,6M | -82% |
| Employees | 2 | — |
Legal name
TRIO PHARMA ApS
CVR number
36499281
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
23. januar 2015
Share capital
DKK 50.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør, bestyrelsesformanden i forening med et andet
bestyrelsesmedlem eller den samlede bestyrelse.
Company purpose
Selskabets formål er at producere, markedsføre, sælge og distribuere naturlægemidler og kosttilskud samt anden hermed beslægtet virksomhed.
Address
Vermlandsgade 51
Phone
+4553843103
Email
info@triopharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -52 | -123 | 28 | 134 | 85 | 361 | -423 | -491 | -289 | -412 |
| Staff expenses | -0 | -115 | -284 | -350 | -424 | -483 | -336 | -371 | -539 | -686 |
| EBITDA | -52 | -238 | -256 | -216 | -335 | -113 | 11.241 | -868 | -828 | -1.028 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -5 | -9 | -0 | -0 | -0 | -0 |
| EBIT | -52 | -238 | -256 | -216 | -339 | -122 | 11.241 | -868 | -828 | -1.028 |
| Net financials | 0 | -6 | -16 | -16 | -22 | -30 | -41 | -40 | -87 | -143 |
| Profit before tax | -52 | -244 | -272 | -232 | -361 | -152 | 11.200 | -889 | -872 | -1.172 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | 2.180 | -0 | -382 | -1 |
| Net profit | -52 | -244 | -272 | -232 | -361 | -152 | 9.020 | -889 | -490 | -1.171 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 33 | 468 | 431 | 342 | 321 | 301 | 241 | 896 | 1.296 | 1.490 |
| Equity | -2 | -246 | -518 | -750 | -1.111 | -1.263 | -44 | -933 | -1.423 | -2.594 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.024 |
| Short-term debt | 35 | 714 | 949 | 1.092 | 1.433 | 1.564 | 284 | 1.829 | 2.718 | 59 |
| Total debt | 35 | 714 | 949 | 1.092 | 1.433 | 1.564 | 284 | 1.829 | 2.718 | 4.083 |
EBITDA margin
-102831600.0%
This company
15.8%
Market median
-650833011% vs market
20162025
Equity ratio
-174.1%
This company
38.2%
Market median
-556% vs market
20162025
Return on equity
-117088000.0%
This company
18.4%
Market median
-636347926% vs market
20162025
Net profit margin
-117088000.0%
This company
8.1%
Market median
-1445530964% vs market
20162025
Asset turnover
-0.28×
This company
1.12×
Market median
-125% vs market
20162025
Debt / equity
1.57×
This company
0.62×
Market median
-153% vs market
20162025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-01-23 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CB Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CHRISTIAN RATJE HOLDING ApS | Company | 90.0% | 90.0% | 2022 |
STINE RATJE HOLDING ApS | Company | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
STINE RATJE HOLDING ApS
TRIO PHARMA ApS Board members of TRIO PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Bo Ratje | Management | 0 companies |
| Michael John Ratje | Chairman | 0 companies |
| Kirstine Laura Ratje-Johansen | Board of Directors | 0 companies |